Monkeypox Testing Market Opportunities, Competitive Landscape & Forecast, 2026-2035

Ngày đăng: 28-07-2026 | Ngày cập nhật: 28-07-2026

Monkeypox Testing Market Outlook and Forecast

The Monkeypox Testing Market is gaining importance as healthcare systems worldwide strengthen infectious disease surveillance, outbreak preparedness, and rapid diagnostic capabilities. The increasing focus on early detection of viral infections, combined with improvements in molecular diagnostics and point-of-care testing technologies, is driving demand for reliable monkeypox testing solutions. Public health agencies, hospitals, diagnostic laboratories, and research institutions continue to invest in advanced testing platforms to enable timely diagnosis, patient management, and disease containment.

The market was valued at USD 2.08 Million in 2025 and is projected to reach USD 3.23 Million by 2035, registering a CAGR of 4.5% during 2026–2035. Continued advancements in molecular diagnostics, increasing awareness of zoonotic diseases, and growing investments in public health infrastructure are expected to support the market's long-term development.

Regional Performance Highlights

North America: North America remains a key market due to advanced healthcare infrastructure, widespread adoption of molecular diagnostic technologies, and strong public health surveillance programs.
Europe: Europe continues to invest in infectious disease preparedness, laboratory capacity expansion, and diagnostic innovation, supporting steady market growth.
Asia Pacific: Asia Pacific is emerging as a promising market, driven by improving healthcare infrastructure, increasing diagnostic awareness, and expanding laboratory testing capabilities.

Market Segmentation Highlights

Polymerase Chain Reaction (PCR): Polymerase Chain Reaction (PCR) held the largest share of the monkeypox testing market in 2025 due to its high sensitivity, specificity, and widespread adoption as the preferred laboratory diagnostic method.
Lateral Flow Assay (LFA): Lateral Flow Assay (LFA) is emerging as the fastest-growing technology segment owing to its rapid turnaround time, portability, and suitability for point-of-care testing.

Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/15121

Top Market Trends

Growing Adoption of Molecular Diagnostic Technologies

Healthcare providers continue to prioritize molecular diagnostic techniques such as PCR for accurate and rapid detection of viral pathogens. Continuous improvements in assay sensitivity, automation, and laboratory workflows are enhancing testing efficiency while supporting faster clinical decision-making during infectious disease outbreaks.

Expansion of Point-of-Care Testing Solutions

The demand for rapid diagnostic tools is encouraging manufacturers to develop portable and easy-to-use point-of-care testing platforms. Lateral flow assays and other rapid diagnostic technologies are improving accessibility in remote locations, emergency response settings, and resource-limited healthcare environments.

Strengthening Global Disease Surveillance Programs

Governments and international health organizations are increasing investments in infectious disease surveillance systems to improve outbreak preparedness. Expanded laboratory networks, enhanced diagnostic capabilities, and coordinated public health monitoring are contributing to sustained demand for monkeypox testing solutions.

Innovation in Multiplex Diagnostic Assays

Diagnostic companies are developing multiplex assays capable of detecting multiple viral pathogens simultaneously. These advanced testing platforms improve laboratory efficiency, optimize resource utilization, and support differential diagnosis for infectious diseases presenting with similar clinical symptoms.

Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/15121

Recent Company Developments

Thermo Fisher Scientific Inc. has continued expanding its molecular diagnostic portfolio by developing advanced PCR-based testing solutions for infectious disease detection.

QIAGEN N.V. has strengthened its molecular diagnostics business through innovative sample preparation technologies and nucleic acid testing solutions supporting infectious disease diagnostics.

Roche Diagnostics has continued investing in automated molecular diagnostic systems that improve laboratory efficiency and diagnostic accuracy.

Abbott Laboratories has expanded its rapid diagnostic capabilities with innovative testing platforms designed to support decentralized healthcare settings.

Danaher Corporation (Cepheid) has enhanced its molecular testing portfolio by advancing automated PCR technologies for rapid infectious disease diagnosis.

Bio-Rad Laboratories, Inc. has continued developing high-performance molecular testing products that improve diagnostic precision and laboratory productivity.

Becton, Dickinson and Company (BD) has expanded its diagnostic solutions portfolio with advanced infectious disease testing technologies for clinical laboratories.

Siemens Healthineers has strengthened its diagnostic offerings through investments in laboratory automation and integrated molecular testing platforms.

bioMérieux SA has continued introducing innovative diagnostic technologies focused on improving infectious disease detection and laboratory efficiency.

Hologic, Inc. has expanded its molecular diagnostics capabilities by advancing automated nucleic acid amplification technologies for clinical testing applications.

Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/15121

Growth Drivers and Challenge

Growth Driver: Rising Focus on Infectious Disease Preparedness

Healthcare systems worldwide are strengthening diagnostic preparedness for emerging infectious diseases through investments in laboratory infrastructure, surveillance programs, and advanced testing technologies. This growing emphasis on rapid detection and outbreak response is supporting continued demand for monkeypox testing solutions.

Growth Driver: Advancements in Rapid Diagnostic Technologies

Continuous innovation in molecular diagnostics, portable testing devices, and rapid immunoassays is improving accessibility, reducing turnaround times, and enabling earlier diagnosis. These technological advancements are expanding testing capabilities across hospitals, diagnostic laboratories, and decentralized healthcare facilities.

Challenge: Fluctuating Testing Demand Following Outbreak Cycles

The monkeypox testing market is influenced by changes in disease incidence and public health priorities. Variations in testing demand following outbreak containment, combined with evolving surveillance requirements and healthcare funding allocations, can create uncertainty for diagnostic manufacturers and service providers.

Read more about this report @

https://www.fundamentalbusinessinsights.com/industry-report/monkeypox-testing-market-15121

Related Reports

About Fundamental Business Insights

Fundamental Business Insights is a global market research and consulting company engaged in providing in-depth market intelligence to industrial sectors, financial institutions, universities, non-profit organizations, and corporations. The company is committed to delivering accurate information to the right stakeholders at the right time in a format that enables logical and informed decision-making. With an experienced team of consultants, Fundamental Business Insights offers syndicated market studies, customized research reports, and strategic consulting services designed to address evolving industry requirements.